New combo pill aims to tame stubborn high blood pressure

NCT ID NCT07704684

Completed Disease control Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether adding Sacubitril/Allisartan to amlodipine can lower blood pressure more effectively than amlodipine alone in people with essential hypertension. Participants are adults aged 18–75 whose blood pressure remains high despite taking amlodipine. The study compares the combination against amlodipine alone over 12 weeks, measuring changes in seated systolic blood pressure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sacubitril/Allisartan and amlodipine
What this could lead to: If successful, this combination could offer a more effective daily pill for people whose blood pressure remains high despite standard treatment.
What could go wrong: This is a mid-stage trial with 376 participants; results may not apply to everyone, and side effects from the combination are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESSENTIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential hypertension hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESSENTIAL HYPERTENSION

Contacts and locations

Show contact details

Locations

Peking University First Hospital

Beijing, Beijing Municipality, 100034, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.